Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.53 |
| ▸ | PHGDH | O43175 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742231 | 0.98 | SMN1; SMN2 (0.83) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL13210615 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL1018513 | 0.87 | SMN1; SMN2 (0.83) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| Lithium Ion SCHEMBL17559401 | 0.84 | SMN1; SMN2 (0.78) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL17559398 | 0.82 | SMN1; SMN2 (0.74) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL2235373 | 0.80 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL7562739 | 0.79 | SMN1; SMN2 (0.81) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL20255520 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL3402254 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB | |
| SCHEMBL31388578 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1GRM5HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| EP-3189041-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 2876/4885ALDH1A1 4190/4885GRM5 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.